Herbal Granules Tested for Slowing Lung Decline in Pulmonary Fibrosis
Tests a Chinese herbal granule against placebo in adults with idiopathic pulmonary fibrosis.
Plain-language title generated from the registry record
Registry title: Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF
Key facts
- Where
- Zhengzhou, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 85 years old?
Source: NCT06914713, who can take part
Where in China
- The First Affiliated Hospital of Henan University of Chinese MedicineZhengzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Henan University of Traditional Chinese Medicine
- Trial code
- NCT06914713
- Record updated
- 16 October 2026
- Original description
This study is to evaluate the clinical efficacy and safety of Jin-shui Huan-xian Formula in retarding the decline of pulmonary function in IPF, generate high - quality clinical evidence, and establish a treatment plan of Jin-shui Huan-xian Formula for retarding the decline of pulmonary function in Idiopathic Pulmonary Fibrosis（IPF）Read full original descriptionShow less
Efficacy Evaluation of Jin-shui Huan-xian Formula in Retarding the Decline of Pulmonary Function in IPF
This study is to evaluate the clinical efficacy and safety of Jin-shui Huan-xian Formula in retarding the decline of pulmonary function in IPF, generate high - quality clinical evidence, and establish a treatment plan of Jin-shui Huan-xian Formula for retarding the decline of pulmonary function in Idiopathic Pulmonary Fibrosis（IPF）
Inclusion: Patients who meet the diagnostic criteria for IPF; Pulmonary function: The percentage of forced vital capacity (FVC) to the predicted value is ≥ 50%; and the percentage of the diffusing capacity of the lung for carbon monoxide (DLCO) to the predicted value is ≥ 30%; Patients who meet the syndrome - differentiation criteria for lung - qi deficiency syndrome, lung - and - kidney qi deficiency syndrome, etc; Aged between 40 and 85 years old; Patients who voluntarily accept the treatment and sign the informed consent.
Exclusion: Patients who have participated in other clinical trials within 1 month before enrollment; Patients complicated with other pulmonary diseases such as chronic obstructive pulmonary disease (COPD), lung cancer, active pulmonary tuberculosis, bronchiectasis, and pulmonary embolism; Patients with severe joint, peripheral nerve, and peripheral vascular diseases that affect limb movement and who are bed - ridden for a long time and cannot complete the six - minute walk test; Patients complicated with severe cardiovascular and cerebrovascular diseases (malignant arrhythmia, unstable angina pectoris, acute myocardial infarction, heart function grade 3 or above, stroke, cerebral hemorrhage, etc.); Patients with unclear consciousness, various mental illnesses, etc., who cannot communicate normally; Patients known to be allergic to any of the test medications and their components; Patients complicated with liver diseases such as cirrhosis or secondary portal hypertension, bleeding caused by esophageal and gastric varices, patients with kidney diseases requiring dialysis or kidney transplantation, or patients with abnormal liver and kidney functions (ALT, AST, and BUN are 1.5 times higher than the upper limit of the normal range, and blood Cr is higher than the upper limit of the normal range); Patients in the acute exacerbation phase of IPF; Pregnant or lactating women and patients with a recent plan for pregnancy.